Son y\u0131llarda kanser tedavisinde immunoterapilerin \u00f6nemi giderek artarken, yeni bir \u00e7al\u0131\u015fman\u0131n sonu\u00e7lar\u0131 bu alanda \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 bir yakla\u015f\u0131m\u0131 g\u00fcndeme getiriyor. Yap\u0131lan ara\u015ft\u0131rmada, ileri evre t\u00fcm\u00f6rlerde kullan\u0131lan imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri (ICI) tedavisi s\u0131ras\u0131nda uygulanan \u00e7oklu t\u00fcm v\u00fccut bilgisayarl\u0131 tomografi (BT) \u0131\u015f\u0131nlamalar\u0131n\u0131n, beklenenin aksine v\u00fccudun antikanser ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131 g\u00fc\u00e7lendirdi\u011fi ortaya kondu. Bu bulgu, radyasyonun kanser tedavisindeki rol\u00fcne ili\u015fkin geleneksel anlay\u0131\u015f\u0131 tersine \u00e7evirirken; t\u00fcm\u00f6r mikro\u00e7evresi \u00fczerinde olumlu etkileri olan d\u00fc\u015f\u00fck doz radyasyonun yeni entegratif tedavi stratejilerinde kullan\u0131labilece\u011fini g\u00f6steriyor.<\/p>\n
\u0130mm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri, \u00f6zellikle ileri evre k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde (KHDAK) devrim niteli\u011finde tedavi se\u00e7enekleri sunmaktad\u0131r. Bu tedavi y\u00f6ntemi, hastan\u0131n ba\u011f\u0131\u015f\u0131kl\u0131k sistemindeki T h\u00fccrelerini aktive ederek t\u00fcm\u00f6r h\u00fccrelerinin tan\u0131nmas\u0131 ve yok edilmesini sa\u011flar. Ancak, klinik uygulamalarda bir\u00e7ok hastada yan\u0131t s\u00fcresi s\u0131n\u0131rl\u0131 kalabilmekte ve remisyonun s\u00fcreklili\u011fi sa\u011flanamamaktad\u0131r. Bu nedenle, imm\u00fcnoterapinin etkinli\u011fini art\u0131rmaya y\u00f6nelik farkl\u0131 y\u00f6ntemler \u00fczerinde yo\u011fun bilimsel ara\u015ft\u0131rmalar s\u00fcrd\u00fcr\u00fclmektedir. Bu ba\u011flamda, radyoterapi ve immunoterapi etkile\u015fimi tart\u0131\u015fmalar\u0131 genellikle y\u00fcksek doz, lokalize radyasyon \u00fczerine yo\u011funla\u015f\u0131rken; tan\u0131sal ama\u00e7l\u0131 BT taramalar\u0131n\u0131n rol\u00fc yeterince ara\u015ft\u0131r\u0131lmam\u0131\u015ft\u0131r.<\/p>\n
Ara\u015ft\u0131rmac\u0131lar, literat\u00fcrde nadiren ele al\u0131nan bu konuya multidisipliner bir yakla\u015f\u0131mla e\u011filerek hem retrospektif klinik verileri hem de geli\u015fmi\u015f hayvan modeli deneylerini kullanm\u0131\u015ft\u0131r. Klinik analizde, ileri evre KHDAK hastalar\u0131 \u00fczerinde, ICI tedavisi s\u0131ras\u0131nda uygulanan t\u00fcm v\u00fccut BT taramalar\u0131n\u0131n s\u0131kl\u0131\u011f\u0131 ile hastalar\u0131n remisyon s\u00fcresi aras\u0131ndaki ili\u015fkiler incelenmi\u015ftir. Paralel olarak fare modellerinde de PD-1 blokaj\u0131 ile e\u015f zamanl\u0131 olarak \u00e7oklu t\u00fcm v\u00fccut BT \u0131\u015f\u0131nlamalar\u0131 ger\u00e7ekle\u015ftirilmi\u015f, t\u00fcm\u00f6r b\u00fcy\u00fcmesi ve imm\u00fcn cevaplar detayl\u0131 \u015fekilde de\u011ferlendirilmi\u015ftir.<\/p>\n
Klinik sonu\u00e7lar, y\u00fcksek say\u0131da BT taramas\u0131 g\u00f6ren hastalarda remisyon s\u00fcresinin anlaml\u0131 \u015fekilde uzad\u0131\u011f\u0131na i\u015faret etmektedir. Bu bulgu, d\u00fc\u015f\u00fck dozlu diagnostik radyasyona maruz kalman\u0131n t\u00fcm\u00f6r ilerlemesini h\u0131zland\u0131raca\u011f\u0131 ya da ikincil kanser riskini art\u0131raca\u011f\u0131na dair endi\u015feleri zay\u0131flatmaktad\u0131r. Aksine, veriler bu uygulaman\u0131n imm\u00fcn sistemi olumlu \u015fekilde mod\u00fcle etti\u011fini ve b\u00f6ylece t\u00fcm\u00f6r kontrol\u00fcn\u00fc destekledi\u011fini g\u00f6stermektedir. Bu sonu\u00e7lar, ileri evre KHDAK hastalar\u0131n\u0131n tedavisinde mevcut protokollerin yeniden de\u011ferlendirilmesini g\u00fcndeme getirmektedir.<\/p>\n
Fare modellerinden elde edilen veriler bu klinik g\u00f6zlemi g\u00fc\u00e7lendirmekte; PD-1 blokaj\u0131 ile birlikte be\u015f kez ger\u00e7ekle\u015ftirilen t\u00fcm v\u00fccut BT \u0131\u015f\u0131nlamalar\u0131n\u0131n, sadece ICI tedavisi alan farelere k\u0131yasla t\u00fcm\u00f6r b\u00fcy\u00fcmesini daha etkin bask\u0131lad\u0131\u011f\u0131 ortaya \u00e7\u0131kmaktad\u0131r. \u0130mm\u00fcn fenotiplendirme ve molek\u00fcler biyoloji y\u00f6ntemleri kullan\u0131larak yap\u0131lan analizlerde, \u0131\u015f\u0131nlama s\u0131kl\u0131\u011f\u0131 ile t\u00fcm\u00f6r dokusundaki CD8+ sitotoksik T lenfosit infiltrasyonunun artt\u0131\u011f\u0131 g\u00f6zlemlenmi\u015ftir. Bu h\u00fccreler, t\u00fcm\u00f6r h\u00fccrelerini hedefleyip \u00f6ld\u00fcren temel ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccreleri olarak kabul edilir.<\/p>\n
Daha da \u00f6nemlisi, infiltrasyona kat\u0131lan CD8+ h\u00fccrelerin b\u00fcy\u00fck k\u0131sm\u0131n\u0131n, interferon gama (IFN\u03b3) salg\u0131lad\u0131\u011f\u0131 tespit edilmi\u015ftir. IFN\u03b3, t\u00fcm\u00f6r kar\u015f\u0131t\u0131 yan\u0131tlar\u0131n tetiklenmesinde kritik rol oynayan pro-inflamatuar bir sitokindir. Single-cell RNA sekanslamas\u0131 ile t\u00fcm\u00f6r i\u00e7indeki lenfositlerin gen ekspresyonu analiz edildi\u011finde; IFN\u03b3 ile ili\u015fkili genlerin ve h\u00fccresel sitolitik fonksiyona katk\u0131 sa\u011flayan genlerin kayda de\u011fer oranda y\u00fckseldi\u011fi saptanm\u0131\u015ft\u0131r. B\u00f6ylece, d\u00fc\u015f\u00fck doz radyasyonun T h\u00fccre say\u0131s\u0131n\u0131 art\u0131rmakla kalmay\u0131p, bu h\u00fccreleri y\u00fcksek derecede etkin ve hedefe y\u00f6nelik \u00f6ld\u00fcr\u00fcc\u00fc bir fenotipe programlad\u0131\u011f\u0131 anla\u015f\u0131lmaktad\u0131r.<\/p>\n
Ara\u015ft\u0131rma, radyasyonun bu dualistik do\u011fas\u0131n\u0131 anlamak a\u00e7\u0131s\u0131ndan da \u00e7arp\u0131c\u0131d\u0131r. Y\u00fcksek doz ve lokalize tedavilerin aksine, d\u00fc\u015f\u00fck doz CT radyasyonu ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131lamak yerine aktive etmektedir. Mekanistik a\u00e7\u0131dan ara\u015ft\u0131rmac\u0131lar, BT radyasyonunun t\u00fcm\u00f6r h\u00fccrelerinde subletal stress yarat\u0131p, hasara ba\u011fl\u0131 molek\u00fcler paternlere (DAMPs) neden olarak t\u00fcm\u00f6r antijenlerinin daha etkili \u015fekilde sunulmas\u0131n\u0131 sa\u011flad\u0131\u011f\u0131n\u0131 \u00f6ne s\u00fcrmektedir. B\u00f6ylece, imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rlerinin aktifle\u015ftirdi\u011fi T h\u00fccreleri t\u00fcm\u00f6r h\u00fccrelerince daha kolay tan\u0131nmakta ve yok edilmektedir. Ayr\u0131ca, radyasyon mikro\u00e7evresel ko\u015fullar\u0131 t\u00fcm\u00f6r infiltrace eden lenfositlerin hareketine m\u00fcsait hale getirmektedir.<\/p>\n
\u00c7al\u0131\u015fmada vurgulanan \u00f6nemli bir detay ise BT \u0131\u015f\u0131nlamalar\u0131n imm\u00fcnoterapi ile yak\u0131n zamanda ve birden fazla seans halinde yap\u0131lmas\u0131n\u0131n gereklili\u011fidir. Fare deneylerinde PD-1 blokaj\u0131 s\u00fcresince be\u015f kez tekrarlanan BT uygulamalar\u0131, optimal imm\u00fcn mod\u00fclasyon i\u00e7in kritik bulunmu\u015ftur. Klinik uygulamalarda da bu zamanlama ve dozaj parametrelerinin netle\u015ftirilmesi, entegratif tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131racak \u00f6nemli bir ad\u0131m olacakt\u0131r.<\/p>\n
G\u00fcvenlik a\u00e7\u0131s\u0131ndan de\u011ferlendirmede, ara\u015ft\u0131rma diagnostik BT taramalar\u0131n\u0131n y\u00fcksek doz radyoterapilere k\u0131yasla \u00e7ok daha d\u00fc\u015f\u00fck iyonize radyasyon i\u00e7erdi\u011fini g\u00f6stermektedir. Bu nedenle, y\u00fcksek dozun yol a\u00e7t\u0131\u011f\u0131 imm\u00fcns\u00fcpresyon ve dokusal hasar riski burada g\u00f6zlenmemektedir. \u00d6zellikle ileri evre kanserli hastalarda, yap\u0131lan \u00e7oklu BT \u0131\u015f\u0131nlamalar\u0131n\u0131n neden oldu\u011fu k\u00fcm\u00fclatif radyasyonun t\u00fcm\u00f6r kontrol\u00fcnden daha fazla zarar verme olas\u0131l\u0131\u011f\u0131n\u0131n d\u00fc\u015f\u00fck oldu\u011fu aktar\u0131lm\u0131\u015ft\u0131r. Buna ra\u011fmen, gen\u00e7 hastalar ya da \u00e7ok say\u0131da tarama gerektiren vaka gruplar\u0131nda uzun d\u00f6nem takip ve risk analizi hala gereklidir.<\/p>\n
Bu bulgular, kanser-immunoloji ve radyasyon onkolojisi alanlar\u0131nda yeni yorumlara kap\u0131 aralamaktad\u0131r. Radyasyonun sadece t\u00fcm\u00f6r h\u00fccrelerine do\u011frudan zarar vermekle kalmay\u0131p, ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131tlar\u0131n\u0131 finete ayar yaparak g\u00fc\u00e7lendirebildi\u011fini ortaya koymaktad\u0131r. Bu da, klinisyenleri tedavi planlama s\u00fcre\u00e7lerinde multi-disipliner ve b\u00fct\u00fcnsel yakla\u015f\u0131mlar benimsemeye zorlamaktad\u0131r.<\/p>\n
Gelecekteki ara\u015ft\u0131rma y\u00f6nleri aras\u0131nda, farkl\u0131 kanser t\u00fcrlerinde ICI tedavisi alt\u0131nda planl\u0131 BT taramas\u0131n\u0131n klinik etkisinin prospektif olarak de\u011ferlendirilmesi yer almaktad\u0131r. Ayr\u0131ca, molek\u00fcler d\u00fczeyde, radyasyonun t\u00fcm\u00f6r h\u00fccreleri ve imm\u00fcn h\u00fccreler \u00fczerindeki biyokimyasal etkilerinin ayr\u0131nt\u0131l\u0131 incelenmesiyle mekanizmalar derinle\u015ftirilecektir. PET-BT gibi di\u011fer g\u00f6r\u00fcnt\u00fcleme modalitelerinin de benzer imm\u00fcn mod\u00fclasyon potansiyelleri olup olmad\u0131\u011f\u0131 ara\u015ft\u0131r\u0131labilir.<\/p>\n
\u0130lave olarak, anti-CTLA-4 gibi di\u011fer imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleriyle ya da yeni geli\u015ftirilen imm\u00fcnoterap\u00f6tik ajanlarla kombinasyon halinde d\u00fc\u015f\u00fck doz BT \u0131\u015f\u0131nlar\u0131n\u0131n verimi incelenmelidir. T\u00fcm bunlar, ki\u015fiselle\u015ftirilmi\u015f t\u0131p yakla\u015f\u0131mlar\u0131n\u0131n \u00f6n\u00fcn\u00fc a\u00e7mak ad\u0131na, t\u00fcm\u00f6r tipine, imm\u00fcnojenik profil ve mutasyon y\u00fck\u00fcne g\u00f6re hasta se\u00e7imi ve biyobelirte\u00e7 geli\u015ftirilmesine zemin haz\u0131rlamaktad\u0131r.<\/p>\n
Sonu\u00e7 olarak, bu \u00e7al\u0131\u015fma standart diagnostik g\u00f6r\u00fcnt\u00fclemeyi tedavi tamamlay\u0131c\u0131 strateji olarak kullanma fikrini hayat ge\u00e7irerek, eri\u015filebilir ve maliyeti g\u00f6rece d\u00fc\u015f\u00fck bir y\u00f6ntemle imm\u00fcnoterapi ba\u015far\u0131s\u0131n\u0131 art\u0131rmay\u0131 hedeflemektedir. Kanser tedavisinde multimodal yakla\u015f\u0131mlar geli\u015ftirilirken, \u0131\u015f\u0131nlaman\u0131n doz, zamanlama ve ba\u011flam sensitif etkilerinin dikkate al\u0131nmas\u0131, hasta sonu\u00e7lar\u0131n\u0131n iyile\u015ftirilmesi a\u00e7\u0131s\u0131ndan kritik \u00f6nem ta\u015f\u0131yacakt\u0131r.<\/p>\n
\u00d6zetle, ileri evre akci\u011fer kanserinde ICI tedavisi s\u0131ras\u0131nda s\u0131k aral\u0131klarla yap\u0131lan t\u00fcm v\u00fccut BT taramalar\u0131n\u0131n, beklenmedik bi\u00e7imde t\u00fcm\u00f6r \u00fczerindeki antit\u00fcm\u00f6r ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131tlar\u0131n\u0131 art\u0131rd\u0131\u011f\u0131 ve hastalarda remisyon s\u00fcresini uzatt\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir. CD8+ T h\u00fccre infiltrasyonu ve fonksiyonel aktivasyonundaki art\u0131\u015f, t\u00fcm\u00f6r kontrol\u00fcn\u00fcn iyile\u015fmesini a\u00e7\u0131klayan \u00f6nemli mekanizmalar olarak tan\u0131mlanm\u0131\u015ft\u0131r. Bu \u00e7al\u0131\u015fma, radyasyon ve imm\u00fcnoterapi aras\u0131ndaki karma\u015f\u0131k etkile\u015fimi yeniden yorumlayarak, onkolojide yeni bir perspektifin kap\u0131lar\u0131n\u0131 a\u00e7maktad\u0131r.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Web References<\/strong>: Doi Referans<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: Son y\u0131llarda kanser tedavisinde immunoterapilerin \u00f6nemi giderek artarken, yeni bir \u00e7al\u0131\u015fman\u0131n sonu\u00e7lar\u0131 bu alanda \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 bir yakla\u015f\u0131m\u0131 g\u00fcndeme getiriyor. Yap\u0131lan ara\u015ft\u0131rmada, ileri evre t\u00fcm\u00f6rlerde kullan\u0131lan imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri (ICI) tedavisi s\u0131ras\u0131nda uygulanan \u00e7oklu t\u00fcm v\u00fccut bilgisayarl\u0131 tomografi (BT) \u0131\u015f\u0131nlamalar\u0131n\u0131n, beklenenin aksine v\u00fccudun antikanser ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131 g\u00fc\u00e7lendirdi\u011fi ortaya kondu. Bu bulgu, radyasyonun kanser tedavisindeki…<\/p>\n","protected":false},"author":1,"featured_media":4742,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[5316,5314,5315,5317,5313],"tmauthors":[],"class_list":{"0":"post-4741","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-dusuk-doz-radyasyonun-tumor-mikrocevresi-etkisi","9":"tag-ileri-evre-kucuk-hucre-disi-akciger-kanserinde-immunoterapi","10":"tag-immun-kontrol-noktasi-inhibitorleri-tedavi-stratejileri","11":"tag-immunoterapi-ve-radyoterapi-entegrasyonu","12":"tag-tum-vucut-bt-isinlamalarinin-immunoterapi-etkisi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/05\/Tum-Vucut-BT-Immunoterapinin-Etkinligini-Artiriyor-1746271806.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=4741"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4741\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/4742"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=4741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=4741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=4741"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=4741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\u0130leri evre k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda imm\u00fcn kontrol noktas\u0131 inhibit\u00f6r\u00fc tedavisi s\u00fcresince s\u0131k aral\u0131klarla uygulanan t\u00fcm v\u00fccut BT taramalar\u0131n\u0131n t\u00fcm\u00f6r mikro\u00e7evresi \u00fczerindeki imm\u00fcnomod\u00fclat\u00f6r etkileri ve tedavi ba\u015far\u0131s\u0131na etkisi.<\/p>\n
\nWhole-body CT scanning radiation improves the immune microenvironment of tumor tissues to enhance the antitumor effect of ICI.<\/p>\n
\nhttps:\/\/doi.org\/10.1186\/s12885-025-14119-7<\/p>\n
\nhttps:\/\/doi.org\/10.1186\/s12885-025-14119-7<\/p>\n
\nScienmag.com<\/p>\n
\nK\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanseri, imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri, bilgisayarl\u0131 tomografi, d\u00fc\u015f\u00fck doz radyasyon, t\u00fcm\u00f6r mikro\u00e7evresi, CD8+ T h\u00fccreleri, interferon gamma, imm\u00fcnoterapi, t\u00fcm\u00f6r ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131, multimodal kanser tedavisi, t\u00fcm v\u00fccut BT taramas\u0131, radyasyon-immunoterapi etkile\u015fimi, ileri evre kanser tedavi stratejileri.<\/p>\n","protected":false},"excerpt":{"rendered":"